✦ LIBER ✦

Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation

✍ Scribed by M. PIHUSCH; A. BACIGALUPO; J. SZER; M. VON DEPKA PRONDZINSKI; B. GASPAR-BLAUDSCHUN; L. HYVELED; B. BRENNER; FOR THE F7BMT-1360 TRIAL INVESTIGATORS

Book ID: 109149147
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 169 KB
Volume: 3
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2005.01523.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

More on: platelet count and the Use of R

More on: platelet count and the Use of Recombinant Factor VIIa for the treatment of Bleeding Complications after Hematopoietic Stem Cell Transplantation

✍ M. MARIETTA; L. FACCHINI; M. GIRARDIS; M. LUPPI; G. TORELLI 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Successful treatment of severe gastroint

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

✍ Gülsüm Emel Pamuk; Murat Taşçi; Erman Öztürk; Muzaffer Demir 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 188 KB

Recombinant human soluble tumor necrosis

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

✍ Alessandro Busca; Franco Locatelli; Filippo Marmont; Cristina Ceretto; Michele F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 pat

Acute bleeding complications in patients

Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 109 and 20 × 109 per L

✍ Shoshan Nevo; Alice K. Fuller; Eric Hartley; Mark E. Borinsky; Georgia B. Vogels 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 227 KB

On-demand treatment of bleeds in haemoph

On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII

✍ B. SØRENSEN; Y. DARGAUD; G. KENET; J. LUSHER; A. MUMFORD; S. PIPE; A. TIEDE 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

Targeted IV busulfan and fludarabine fol

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

✍ Joseph Pidala; Jaime Roman-Diaz; Jongphil Kim; Taiga Nishihori; Janelle Perkins; 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 271 KB